Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hanmi Surprises Again, Signing Big Diabetes Deal With Sanofi

This article was originally published in PharmAsia News

Executive Summary

South Korea's Hanmi Pharmaceutical is making the history books. Following its record-setting agreements with Lilly and Boehringer Ingelheim earlier this year, it has now inked a substantially bigger licensing out pact worth up to €3.9bn with Sanofi for its diabetes Quantum Project. While the deal will buoy the portfolio of the leading global diabetes player, it offers no quick fix, analysts caution.


Related Content

Deal Watch: Sanofi Begins 2017 By Ending Vaccine JV, Completing Swap With Boehringer


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts